Malaria Nanobody
Malaria
Pre-clinicalActive
Key Facts
About VicuTec Biologicals
VicuTec Biologicals is a private, preclinical-stage biotech based in Munich and Dortmund, Germany, developing a robust nanobody platform. The company's technology, originating from the Max Planck Institute and University Medical Center Göttingen, enables rapid, cost-effective production of highly potent nanobodies in microbial systems. Its initial pipeline targets major infectious diseases including COVID-19, MRSA, Tuberculosis, and Malaria, with backing from the EU Malaria Fund and strategic academic partnerships.
View full company profileTherapeutic Areas
Other Malaria Drugs
| Drug | Company | Phase |
|---|---|---|
| Vaxine Malaria Vaccine | Vaxine | Preclinical |
| Malaria Vaccine | VLP Biotech | Pre-clinical |
| Malaria-on-a-Chip Model | Hesperos | Pre-clinical |
| Malaria Antibodies | new/era/mabs | Research/Pre-clinical |
| Dendritic Cell Vaccine | MegaNano BioTech | Pre-clinical |
| Malaria | Keltic Pharma Therapeutics | Pre-clinical |
| Antibody Programs (Malaria) | Ibex Biosciences | Pre-clinical |
| Malaria RDTs | Access Bio | Commercial |